Toward an Effective Treatment of Alzheimer's Disease
Authors: JOHN P. BLASS
Journal: Annals of Internal Medicine (1983)

Editorials1 February 1983Toward an Effective Treatment of Alzheimer's DiseaseJOHN P. BLASS, M.D., MARC E. WEKSLER, M.D.JOHN P. BLASS, M.D., MARC E. WEKSLER, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-2-251 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe development of an effective treatment for Alzheimer's disease is one of the most pressing needs facing medicine today. This age-related disease has become increasingly prevalent as our population of elderly persons has grown and now affects at least 4 million persons in the United States. Patients with Alzheimer's disease fill more than one half of the beds in nursing homes (1). Additional disability occurs because patients with even mild dementia are unable to comply with medical treatment for other diseases.Recent advances in our understanding of Alzheimer's disease as well as recently completed therapeutic trials suggest that a treatment...References1. PLUM F. Dementia: an approaching epidemic. Nature. 1979;279:372-3. CrossrefMedlineGoogle Scholar2. BOWENWHITESPILLANE DPJ. Accelerated ageing or selective neuronal loss as an important cause of dementia. Lancet. 1979;1:11-4. MedlineGoogle Scholar3. WHITEHOUSEPRICESTRUBBCLARKCOYLEDELONG PDRAJM. Alzheimer's disease and senile dementia: loss of neurones in the basal forebrain. Science. 1982;215:1237-9. CrossrefMedlineGoogle Scholar4. SIMSSMITHDAVISONFLACKSNOWDENNEARY NCARJD. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet. 1980;1:333-5. CrossrefMedlineGoogle Scholar5. RICHTERPERRYTOMLINSON JEB. Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease. Life Sci. 1980;26:1683-9. CrossrefMedlineGoogle Scholar6. DRACHMANLEAVITT DJ. Human memory and the cholinergic system: a relationship to aging. Arch Neurol. 1974;30:113-21. CrossrefMedlineGoogle Scholar7. HIRSCHWURTMAN MR. Lecithin consumption increases acetylcholine concentrations in rat brain and adrenal gland. Science. 1978;202:223-5. CrossrefMedlineGoogle Scholar8. GROWDONHIRSCHWURTMANWIENER JMRW. Oral choline administration to patients with tardive dyskenesia. N Engl J Med. 1977;297:524-7. CrossrefMedlineGoogle Scholar9. ETIENNEDASTORGAUTHEIRLUDWICKCOLLIER PDSRB. Alzheimer disease: lack of effect of lecithin treatment for three months. Neurology. 1981;31:1552-4. CrossrefMedlineGoogle Scholar10. DAVISMOHS KR. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry. 1982;139:1421-4. [See abstract in the "From Other Pages" section in this issue.] CrossrefMedlineGoogle Scholar11. DAVISMOHSTINKLENBERG KRJ. Physostigmine: improvement of long term memory processes in normal humans. Science. 1978;201:272-4. CrossrefMedlineGoogle Scholar12. THALFULDMASURSHARPLESS LPDN. Oral physostigmine and lecithin improve memory in Alzheimer's disease. Ann Neurol. 1983; (In press). CrossrefMedlineGoogle Scholar13. PETERSLEVIN BH. Effect of physostigmine and lecithin on memory in Alzheimer's disease. Ann Neurol. 1979;6:219-21. CrossrefMedlineGoogle Scholar14. SUMMERSVIESSELMANMARSHCANDELARA WJGK. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry. 1981;16:145-53. MedlineGoogle Scholar15. CHRISTIESHERINGFERGUSONGLEN JAJA. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry. 1981;138:46-50. CrossrefMedlineGoogle Scholar16. MURAMOTOSUGISHITASUGITATOYOKURA OMHY. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. Arch Neurol. 1979;36:501-3. CrossrefMedlineGoogle Scholar17. SMITHSWASH CM. Physostigmine in Alzheimer's disease [Letter]. Lancet. 1979;1:42. CrossrefMedlineGoogle Scholar18. ASHFORDSOLDINGERSCHAEFFERCOCHRANJARVIK JSJLL. Physostigmine and its effect on six patients with dementia. Am J Psychiatry. 1981;138:829-30. CrossrefMedlineGoogle Scholar19. CAINE E. Cholinomimetic treatment fails to improve memory disorders [Letter]. N Engl J Med. 1980;303:585-6. CrossrefMedlineGoogle Scholar20. GOTTFRIES C. Biochemical aspects of dementia. In: VAN PRAAG HM, LEDER MH, RAFAELSEN OJ, eds. Handbook of Biological Psychiatry: Vol. IV. Brain Mechanisms and Abnormal Behavior. New York: Marcel Dekker, Inc.; 1980. Google Scholar21. THOMAS L. On the problem of dementia. Discover. 1981;August:34-6. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JOHN P. BLASS, M.D.; MARC E. WEKSLER, M.D.Affiliations: Cornell University Medical College New York, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Compression of MorbidityNon-Cholinergic Therapies of DementiaEffects of Cholinergic Enhancement Therapies on Memory Function in Alzheimer's Disease: A Meta-Analysis of the LiteratureOn the pathogenesis and therapy of dementia of the Alzheimer type: Some neuropathological biochemical genetic and pharmacotherapeutic considerationsDrug therapy of Alzheimer's disease: Realistic or not?The future of disease and treatmentTHERAPEUTIC PROGRESS—REVIEW XVIII ALZHEIMER'S DISEASEAlzheimer's diseasePharmacotherapy of Mental Disorders of Old AgeAlzheimer's Disease: Clinical Features, Pathogenesis, and TreatmentAlzheimer's disease 1 February 1983Volume 98, Issue 2Page: 251-253KeywordsAlzheimer diseaseDementiaDisabilitiesElderlyNursing homes ePublished: 1 December 2008 Issue Published: 1 February 1983 PDF downloadLoading ...